In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Dual (DAT) or Triple (TAT) Antithrombotic Therapy

Dual (DAT) or triple (TAT) antithrombotic therapy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI)

Experts' Introduction

This topic is of high interest, because triple therapy, consisting of low-dose aspirin clopidogrel and an oral anticoagulant (OAC), is theoretically of importance, but associated with increased bleeding hazard. Recent studies (PIONEER AF, RESIDUAL PCI and AUGUSTUS) have shown that NOACs should be preferred over vitamin K antagonists. European guidelines and position papers make a strong point for at least 1 month of TAT especially in patients with an increased ischemic risk.“



Prof. Kurt Huber

Interventional cardiologist, Vienna, Austria



Acute Cardiovascular Care Congress Resources

ESC 365 visual

Access the session from Acute Cardiovascular care 2019



Clinical Decision-Making Toolkit


Access the toolkit

Free chapter on Secondary Prevention after ACS



webinars.jpgLong-term management after an ACS in the current era


European Heart Journal - Acute Cardiovascular Care

Journal-Acute-Cardiovascular-Care-EHJ.pngAccess a selection of relevant scientific papers in the field:

EAPCI resources

A Position Statement from the EAPCI Women Committee

EAPCI Webinar : Always triple therapy for Afib patients undergoing PCI irrespective of the bleeding risk status?